医院传染病检查市场 - 全球产业规模、份额、趋势、机会、预测：按检测类型、感染类型、产品、类型、地区和竞争对手划分，2021-2031年

全球医院感染检测市场预计将从 2025 年的 52.9 亿美元大幅成长至 2031 年的 83.4 亿美元，复合年增长率为 7.88%。

该市场涵盖一系列筛检程序和诊断测试，用于检测医疗机构内传播给患者的病毒和细菌等传染性病原体。推动这一市场成长的关键因素包括：医院感染发生率不断上升、老年人口不断增长（老年人极易感染此类疾病）、政府加强感染控制措施以及合理使用抗菌药物方案的必要实施。

儘管有这些成长要素，但市场仍面临一个重大障碍：先进分子诊断的高成本限制了其在资源匮乏地区的普及。然而，鑑于抗生素抗药性病原体带来的严重负担，对这些检测解决方案的需求仍然强劲。世界卫生组织（世卫组织）的数据凸显了这种迫切性，预计到2024年，全球将出现约1.36亿例抗生素抗药性医疗相关感染疾病病例，凸显了有效诊断干预措施的迫切需求。

市场驱动因素

快速诊断技术的进步正在从根本上改变全球医院感染检测市场，使病原体检测更加早期和精确。从传统的培养方法转向先进的分子诊断技术，特别是综合征检测，使得医疗专业人员能够在数小时内而非数天内识别多种感染性病原体。这对于快速启动抗生素治疗和改善患者预后至关重要。这些创新技术的商业性可行性在其日益普及的应用中得到了充分体现。例如，生物梅里埃公司在其2024年9月发布的「2024财年上半年财务业绩报告」中指出，其用于诊断脑膜炎和败血症等疾病的BIOFIRE非呼吸道病原体检测组合的有机销售额增长了19%。

同时，随着多重抗药性病原体的威胁日益加剧，医疗机构争相对抗超级细菌，对这类先进检测解决方案的需求也日益增长。随着抗药性机制的演变和标准抗生素疗效的下降，精准诊断对于制定合理使用抗菌药物的指南和预防感染传播至关重要。长期预测也凸显了这种迫切性。惠康基金会2024年9月的报告预测，2025年至2050年间，将有超过3,900万人死于抗药性细菌感染疾病。 2024年7月，美国疾病管制与预防中心（CDC）宣布，多重抗药性真菌耳Auris的临床病例自2019年以来增加了约五倍。

市场挑战

先进分子诊断的高昂成本是限制全球医院感染检测市场成长的主要障碍。医疗机构，尤其是资源有限的机构，在权衡采用最先进的筛检工具与必要的营运成本时，往往面临艰难的抉择。因此，准确但昂贵的分子检测往往难以普及，许多医疗机构被迫依赖传统的、成本较低的诊断方法，这可能导致必要的治疗和感染控制通讯协定的延迟。

这种财政限制也体现在诊断技术投资占整体医疗保健支出比例相对较低。如果检测预算拨款与其他医疗保健领域相比仍然过低，市场扩张将受到阻碍。根据欧洲医疗技术协会（MedTech Europe）预测，到2024年，体外诊断支出预计仅占医疗保健总支出的0.6%。这项数据凸显了严重的预算限制，阻碍了先进检测解决方案的普及，也使市场无法充分满足感染疾病带来的需求。

市场趋势

即时检测（POC​​）的普及使得医院感染的检测分散化，医护人员无需等待中心检查室的检测结果，即可在患者床边直接识别病原体。这一转变显着缩短了检测结果的返回时间，从而能够在疫情爆发时即时做出隔离和治疗决策，这对于防止感染扩散至关重要，尤其是在高风险病房。这一趋势对市场的影响体现在分散式分子平台的快速商业性应用上。例如，2025年3月，生物梅里埃公司报告称，其SPOTFIRE照护现场解决方案的年销售额已达到9,500万欧元，这主要得益于医疗机构中不断扩大的应用群体。

同时，即时数位监测系统正显着普及，用于监测整个医疗网路中的感染率和抗生素抗药性模式。这些系统整合了住院和手术数据，识别高风险区域，并确保符合感染控制标准，从而为管理人员提供持续的回馈机制。参与这些监测计画推动了对定期检测的需求，英国卫生安全局2025年12月的报告显示，提交监测分析的手术数量同比增长7.9%，这反映出医疗机构对监测义务的遵守程度有所提高。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球医院传染病检查市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依检测类型（分子检测、常规检测）
  • 按类型分类的感染疾病（尿道感染、肺炎、手术部位感染、血流感染疾病、其他）
  • 依产品分类（耗材、设备）
  • 依类型（血液检查、尿液检查）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美医疗保健传染病检查市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲医院传染病检查市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区医院传染病检查市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲医院传染病检查市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲医院传染病检查市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球医院传染病检查市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• bioMerieux SA
• Abbott Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare Private Limited
• Becton, Dickinson and Company
• Bioscience, Inc.
• QIAGEN NV
• Thermo Fisher Scientific Inc
• Hologic, Inc.
• Meridian Bioscience, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Hospital Acquired Disease Testing Market is projected to experience significant growth, expanding from USD 5.29 Billion in 2025 to USD 8.34 Billion by 2031, reflecting a CAGR of 7.88%. This market encompasses various screening procedures and diagnostic assays intended to detect infectious agents, including viruses and bacteria, that are transmitted to patients within medical environments. Key drivers accelerating this growth include the increasing incidence of nosocomial infections and a growing geriatric demographic that is highly vulnerable to such conditions, alongside strict government mandates for infection control and the essential adoption of antimicrobial stewardship programs.

Despite these growth factors, the market faces a substantial obstacle in the form of high costs linked to advanced molecular diagnostics, which restricts their deployment in regions with limited resources. Nevertheless, the demand for these testing solutions remains acute given the heavy burden of resistant pathogens. Data from the World Health Organization underscores this urgency, estimating that in 2024, approximately 136 million antibiotic-resistant healthcare-associated infections occurred globally, highlighting the critical need for effective diagnostic interventions.

Market Driver

Advancements in rapid diagnostic technologies are fundamentally transforming the Global Hospital Acquired Disease Testing Market by facilitating earlier and more precise pathogen detection. The shift from conventional culture-based techniques to sophisticated molecular diagnostics, particularly syndromic testing, enables medical professionals to identify multiple infectious agents in hours instead of days, which is crucial for timely antimicrobial therapy and improved patient outcomes. The commercial viability of these innovations is evident in their increasing adoption; for example, bioMerieux reported in their 'First-Half 2024 Financial Results' in September 2024 that organic sales of their BIOFIRE non-respiratory panels, essential for diagnosing conditions like meningitis and sepsis, rose by 19%.

At the same time, the escalating threat of multidrug-resistant pathogens is driving the necessity for these advanced testing solutions as healthcare facilities fight to control superbugs. As resistance mechanisms evolve and standard antibiotics become less effective, precise diagnostics are essential for guiding antimicrobial stewardship and preventing outbreaks. This urgency is emphasized by long-term forecasts; a September 2024 report by Wellcome predicts over 39 million deaths will be attributed to antibiotic-resistant infections between 2025 and 2050, while the Centers for Disease Control and Prevention noted in July 2024 that reported clinical cases of the multidrug-resistant fungus Candida auris increased nearly five-fold since 2019.

Market Challenge

The substantial expense associated with advanced molecular diagnostics poses a significant barrier to the growth of the Global Hospital Acquired Disease Testing Market. Healthcare institutions, particularly those in resource-limited settings, often face difficult decisions when balancing the acquisition of cutting-edge screening tools against essential operational costs. Consequently, the adoption of precise yet costly molecular assays is often limited, compelling many providers to depend on traditional, less expensive diagnostic methods that may delay necessary treatment and infection control protocols.

This financial constraint is further illustrated by the relatively low investment in diagnostic technologies compared to overall healthcare spending. Market expansion is stifled when budgetary allocations for testing remain disproportionately small relative to other medical verticals. According to MedTech Europe, expenditure on in vitro diagnostics in 2024 was estimated to account for only 0.6% of total healthcare spending. This statistic underscores the severe budgetary limitations that hinder the uptake of advanced testing solutions, preventing the market from fully addressing the demand generated by the prevalence of infectious diseases.

Market Trends

The expansion of Point-of-Care (POC) testing is decentralizing the detection of hospital-acquired diseases, enabling healthcare providers to identify pathogens directly at the bedside rather than waiting for central laboratory results. This transition significantly lowers turnaround times, allowing for immediate isolation and treatment decisions that are vital for containing outbreaks in sensitive wards. The market impact of this trend is highlighted by the swift commercial adoption of decentralized molecular platforms; for instance, bioMerieux reported in March 2025 that sales of its SPOTFIRE point-of-care solution reached €95 million for the year, driven by a growing installed base across medical facilities.

Concurrently, there is a notable shift toward real-time digital surveillance systems designed to monitor infection rates and antimicrobial resistance patterns throughout healthcare networks. These systems compile data from inpatient stays and surgical procedures to pinpoint high-risk areas and ensure compliance with infection control standards, creating a continuous feedback loop for administrators. Participation in these monitoring programs is fueling demand for consistent testing, as evidenced by the UK Health Security Agency's December 2025 report, which noted a 7.9% increase in the volume of surgical procedures submitted for surveillance analysis compared to the previous year, reflecting increased adherence to monitoring mandates.

Key Market Players

• bioMerieux SA
• Abbott Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare Private Limited
• Becton, Dickinson and Company
• Bioscience, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc
• Hologic, Inc.
• Meridian Bioscience, Inc

Report Scope

In this report, the Global Hospital Acquired Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hospital Acquired Disease Testing Market, By Test Type

• Molecular
• Conventional

Hospital Acquired Disease Testing Market, By Infection Type

• UTI
• Pneumonia
• Surgical Site Infection
• Blood Stream Infections
• Others

Hospital Acquired Disease Testing Market, By Product

• Consumables
• Instruments

Hospital Acquired Disease Testing Market, By Type

• Blood Tests
• Urinalysis

Hospital Acquired Disease Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hospital Acquired Disease Testing Market.

Available Customizations:

Global Hospital Acquired Disease Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hospital Acquired Disease Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Molecular, Conventional)
  • 5.2.2. By Infection Type (UTI, Pneumonia, Surgical Site Infection, Blood Stream Infections, Others)
  • 5.2.3. By Product (Consumables, Instruments)
  • 5.2.4. By Type (Blood Tests, Urinalysis)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Hospital Acquired Disease Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Infection Type
  • 6.2.3. By Product
  • 6.2.4. By Type
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hospital Acquired Disease Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Infection Type
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By Type
  • 6.3.2. Canada Hospital Acquired Disease Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Infection Type
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By Type
  • 6.3.3. Mexico Hospital Acquired Disease Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Infection Type
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By Type

7. Europe Hospital Acquired Disease Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Infection Type
  • 7.2.3. By Product
  • 7.2.4. By Type
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hospital Acquired Disease Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Infection Type
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By Type
  • 7.3.2. France Hospital Acquired Disease Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Infection Type
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By Type
  • 7.3.3. United Kingdom Hospital Acquired Disease Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Infection Type
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By Type
  • 7.3.4. Italy Hospital Acquired Disease Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Infection Type
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By Type
  • 7.3.5. Spain Hospital Acquired Disease Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Infection Type
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By Type

8. Asia Pacific Hospital Acquired Disease Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Infection Type
  • 8.2.3. By Product
  • 8.2.4. By Type
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hospital Acquired Disease Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Infection Type
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By Type
  • 8.3.2. India Hospital Acquired Disease Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Infection Type
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By Type
  • 8.3.3. Japan Hospital Acquired Disease Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Infection Type
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By Type
  • 8.3.4. South Korea Hospital Acquired Disease Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Infection Type
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By Type
  • 8.3.5. Australia Hospital Acquired Disease Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Infection Type
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By Type

9. Middle East & Africa Hospital Acquired Disease Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Infection Type
  • 9.2.3. By Product
  • 9.2.4. By Type
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hospital Acquired Disease Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Infection Type
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By Type
  • 9.3.2. UAE Hospital Acquired Disease Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Infection Type
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By Type
  • 9.3.3. South Africa Hospital Acquired Disease Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Infection Type
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By Type

10. South America Hospital Acquired Disease Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Infection Type
  • 10.2.3. By Product
  • 10.2.4. By Type
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hospital Acquired Disease Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Infection Type
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By Type
  • 10.3.2. Colombia Hospital Acquired Disease Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Infection Type
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By Type
  • 10.3.3. Argentina Hospital Acquired Disease Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Infection Type
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hospital Acquired Disease Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. bioMerieux SA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. Siemens Healthcare Private Limited
• 15.5. Becton, Dickinson and Company
• 15.6. Bioscience, Inc.
• 15.7. QIAGEN N.V.
• 15.8. Thermo Fisher Scientific Inc
• 15.9. Hologic, Inc.
• 15.10. Meridian Bioscience, Inc

16. Strategic Recommendations

17. About Us & Disclaimer